NASDAQ · QDEL
Healthcare · Medical - Instruments & Supplies
$10.70
Down-$2.14 (-16.67%)
Updated Nov 8, 2026, 3:23 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · QDEL
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 6, 2026
QDEL closed at $10.70 after 20 trading sessions, down 19.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | $12.56 | $12.69 | $10.66 | $10.70 | 2.82M |
| Nov 5, 2026 | $14.13 | $14.33 | $11.6625 | $12.84 | 4.13M |
| Nov 4, 2026 | $14.61 | $14.85 | $13.57 | $14.35 | 3.28M |
| Nov 3, 2026 | $14.17 | $14.59 | $13.37 | $14.09 | 3.57M |
| Nov 2, 2026 | $13.53 | $14.28 | $13.09 | $14.03 | 2.86M |
| Oct 30, 2026 | $13.445 | $13.505 | $12.48 | $13.25 | 1.74M |
| Oct 29, 2026 | $14.00 | $14.26 | $13.635 | $13.76 | 1.51M |
| Oct 28, 2026 | $13.45 | $14.56 | $13.45 | $14.01 | 1.62M |
| Oct 27, 2026 | $13.73 | $14.355 | $13.51 | $13.59 | 2.08M |
| Oct 26, 2026 | $13.71 | $13.90 | $12.57 | $13.77 | 2.18M |
| Oct 23, 2026 | $13.24 | $13.81 | $12.45 | $13.73 | 1.41M |
| Oct 22, 2026 | $14.01 | $14.63 | $13.27 | $13.48 | 1.64M |
| Oct 21, 2026 | $13.73 | $14.65 | $13.42 | $14.08 | 3.32M |
| Oct 20, 2026 | $12.86 | $14.50 | $12.82 | $14.21 | 2.64M |
| Oct 19, 2026 | $12.94 | $13.48 | $12.685 | $12.76 | 1.43M |
| Oct 16, 2026 | $13.77 | $14.015 | $12.79 | $12.91 | 1.79M |
| Oct 15, 2026 | $13.86 | $14.155 | $13.65 | $13.91 | 2M |
| Oct 14, 2026 | $13.90 | $14.65 | $13.64 | $13.87 | 2.15M |
| Oct 13, 2026 | $13.40 | $14.61 | $13.33 | $14.10 | 3.05M |
| Oct 12, 2026 | $13.44 | $13.50 | $13.04 | $13.25 | 2.62M |
The latest Smart Investors Daily articles mentioning QDEL.
Company
Market Activity
Research & News
QDEL research
Company profile and research snapshot.
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 8, 2026 | Citigroup | Neutral | — |
| Jul 1, 2026 | JP Morgan | Underweight | — |
| May 7, 2026 | Jefferies | Hold | — |
| May 6, 2026 | Citigroup | Neutral | — |
| Apr 10, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Benzinga · Oct 13, 2026
QuidelOrtho (NASDAQ:QDEL) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to
Yahoo · Oct 12, 2026
Over the past six months, QuidelOrtho’s shares (currently trading at $13.31) have posted a disappointing 17.3% loss, well below the S&P 500’s 12.8% gain. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Benzinga · Apr 10, 2026
UBS analyst Lu Li maintains QuidelOrtho (NASDAQ:QDEL) with a Neutral and lowers the price target from $30 to $17.
Yahoo · Mar 3, 2026
Over the past six months, QuidelOrtho’s shares (currently trading at $22.11) have posted a disappointing 19.9% loss, well below the S&P 500’s 6.6% gain. This might have investors contemplating their next move.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning QDEL.
